Withdrawal of the marketing authorisation application
On 13 July 2007, Ark Therapeutics officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Cerepro, for the treatment of patients with operable high-grade glioma. Cerepro was designated an orphan medicinal product on 6 February 2002.
|International non-proprietary name (INN) or common name||
|Date of withdrawal||
|Company making the application|
Withdrawal assessment report for Cerepro (PDF/167.04 KB)Adopted
First published: 14/04/2009
Last updated: 14/04/2009
Ark Therapeutics withdraws its marketing authorisation application for Cerepro (PDF/27.31 KB)
First published: 20/07/2007
Last updated: 20/07/2007
Withdrawal letter : Cerepro (PDF/21.23 KB)
First published: 16/07/2007
Last updated: 16/07/2007
Questions and answers on the withdrawal of the marketing application for Cerepro (PDF/51.03 KB)
First published: 19/07/2007
Last updated: 19/07/2007
Related information on withdrawals
A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.
An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').